Dow (DOW)

The sleeper story is that Dow's growth this quarter was capacity-limited, not demand-limited: management admitted on the call that Middle East JV constraints cost them volume they could have sold, with ex-Middle East PSP volume up 2% even as headline PSP volume was reported down 1%, which means the pricing power showing up in PE and MDI margins has more room to run once Sadara, Equate, and the Thailand cracker normalize. The obvious headline, '13% sales growth, every segment up', is real but sits on top of a Q3 EBITDA guide of 'approximately $1.7 billion' that was reported as only 'more than $1.5 billion', a vaguer figure than usual right where the news is worse. The binding constraint right now is physical: idled derivative units and logistics bottlenecks in the Gulf region, not Dow's own cost structure or demand. The most revealing line of the call was management's blunt admission: 'Yes, we could have... if we had more capacity, we would have sold it'. My view changes if Sadara liquids and the Equate derivative units restart meaningfully before year end; if they don't, the pricing story stays capacity-capped and the quietly-dropped $6B self-help bridge becomes the more important thing to re-anchor on next call.